Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma

Immunology

Volumn 122, Issue 4, 2007, Pages 615-622

  Kim, Chang Hyun ^a,b   Woo, Sun Je ^b   Park, Jung Sun ^b   Kim, Hye Sung ^b   Park, Mi Young ^b   Park, Sung Dong ^b   Hong, Yong Kil ^a,b   Kim, Tai Gyu ^a,b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Dendritic cells; Glioma; Human immunodeficiency virus Tat; Surviving; Temozolomide

Indexed keywords

CD8 ANTIGEN; DENDRITIC CELL VACCINE; SURVIVIN; TEMOZOLOMIDE; TRANSACTIVATOR PROTEIN; TRANSACTIVATOR PROTEIN PLUS SURVIVIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN SPECIFICITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; GLIOMA CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNITY;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS REGULATORY PROTEINS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DACARBAZINE; DENDRITIC CELLS; FEMALE; GLIOMA; IMMUNITY, CELLULAR; MICE; MICE, INBRED C57BL; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; RECOMBINANT FUSION PROTEINS; SPLEEN; SURVIVAL ANALYSIS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSDUCTION, GENETIC; TREATMENT OUTCOME;

EID: 35948930300     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2007.02680.x     Document Type: Article

References (38)

1. Nazzaro JM, Neuwelt EA. The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults. J Neurosurg 2006 73: 331 44.
2. Surawicz TS, Davis F, Freels S, Laws ER Jr., Menck HR. Brain tumor survival: results from the National Cancer Data Base. J Neurooncol 1998 40: 15 60.
3. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000 6: 2585 97.
4. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005 352: 987 96.
5. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000 6: 2585 97.
6. Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 2005 65: 8059 64.
7. Gianani R, Jarboe E, Orlicky D, et al. Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol 2001 32: 119 25.
8. Velculescu VE, Madden SL, Zhang L, et al. Analysis of human transcriptosomes. Nat Genet 1999 23: 387 8.
9. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003 3: 46 54.
10. Chakravarti A, Noll E, Black PM, et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 2002 20: 1063 8.
11. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 2006 5: 1087 98.
12. Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, thor Straten P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 2001 61: 5964 8.
13. Zeis M, Siegel S, Wagner A, et al. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol 2003 170: 5391 7.
14. Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T, Altieri DC. Therapeutic targeting of the survivin pathway in cancer. Initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 2003 9: 2683 92.
15. Shibagaki N, Udey MC. Dendritic cells transduced with protein antigen induce cytotoxic lymphocytes and elicit antitumor immunity. J Immunol 2002 168: 2393 401.
16. + T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J Clin Invest 2002 109: 1463 70.
17. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, Barsoum J. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA 1994 91: 664 8.
18. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999 285: 1569 72.
19. Kim CH, Hong MJ, Park SD, et al. Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12. Cancer Immunol Immunother 2006 55: 1309 19.
20. Hong YK, Chung DS, Joe YA, et al. Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon-beta treatment at early stage of tumor development. Clin Cancer Res 2000 6: 3354 60.
21. Park SD, Kim CH, Kim CK, Park JA, Sohn HJ, Hong YK, Kim TG. Cross-priming by temozolomide enhances anti-tumor immunity of dendritic cells vaccination in murine brain tumor model. Vaccine 2007 25: 3485 91.
22. Yamanaka R, Yajima N, Abe T, et al. Dendritic cell-based glioma immunotherapy. Int J Oncol 2003 23: 5 15.
23. Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 2001 7: 2168 81.
24. Constam DB, Philipp J, Malipiero UV, ten Dijke P, Schachner M, Fontana A. Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J Immunol 1992 148: 1404 10.
25. Chen Q, Daniel V, Maher DW, Hersey P. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 1994 56: 755 60.
26. Lake RA, Robinson BW. Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 2005 5: 397 405.
27. Bourquin C, Schreiber S, Beck S, Hartmann G, Endres S. Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer. Int J Cancer 2006 118: 2790 5.
28. Kim DT, Mitchell DJ, Brockstedt DG, et al. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J Immunol 1997 159: 1666 8.
29. Mitsui H, Inozume T, Kitamura R, Shibagaki N, Shimada S. Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity. J Invest Dermatol 2006 126: 1804 12.
30. Schwarze SR, Hruska KA, Dowdy SF. Protein transduction: unrestricted delivery into all cells? Trends Cell Biol 2000 10: 290 5.
31. Morris MC, Depollier J, Mery J, Heitz F, Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 2001 19: 1173 6.
32. Ho A, Schwarze SR, Mermelstein SJ, Waksman G, Dowdy SF. Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res 2001 61: 474 7.
33. Roos WP, Batista LF, Naumann SC, et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O(6)-methylguanine. Oncogene 2007 26: 186 97.
34. Tentori L, Leonetti C, Scarsella M, et al. Systemic administration of GPI 15427, a novel poly (ADP-ribose) polymerase-1 inhibitor, increases the anti-tumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 2003 9: 5370 9.
35. Nowak AK, Lake RA, Marzo AL, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 2003 170: 4905 13.
36. Machiels JP, Reilly RT, Emens LA, et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the anti-tumor immune response of granulocyte/macrophage- colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 2001 61: 3689 97.
37. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide, which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004 34: 336 44.
38. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006 6: 295 307.